DiaMedica Therapeutics, Inc. (DMAC) Shows Strong Momentum: Is It a Good Investment?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2025
0mins
Should l Buy DMAC?
Source: NASDAQ.COM
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics, such as price changes and earnings estimate revisions.
DiaMedica Therapeutics, Inc. (DMAC) Performance: DMAC has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with significant recent price increases, including an 86.86% rise over the past quarter, outperforming both its industry and the S&P 500.
Earnings Estimate Trends: DMAC has seen positive earnings estimate revisions, with one estimate moving higher recently, indicating potential for future growth and contributing to its favorable momentum score.
Quantum Computing Insights: Quantum computing is rapidly advancing, with major tech companies integrating it into their operations. Investment strategist Kevin Cook highlights stocks that may lead in this emerging field, suggesting a significant opportunity for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DMAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DMAC
Wall Street analysts forecast DMAC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.710
Low
12.00
Averages
17.00
High
25.00
Current: 7.710
Low
12.00
Averages
17.00
High
25.00
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
DiaMedica to Participate in Three Investment Conferences
- Investment Conference Schedule: DiaMedica Therapeutics will participate in the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, in Boston, where CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in a fireside chat, showcasing the company's latest advancements in treating serious ischemic diseases.
- Global Healthcare Conference: The company will also attend the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where CEO Rick Pauls will conduct a fireside chat, further enhancing the company's visibility among investors.
- Presentation Opportunity: On March 11, 2026, at the Leerink Partners Global Healthcare Conference, Rick Pauls will present the company, aiming to attract potential investors and highlight DiaMedica's R&D achievements and future plans.
- Management Interaction: DiaMedica encourages arrangements for 1-on-1 meetings with management to facilitate deeper engagement with investors, further strengthening the relationship between the company and its investors.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Incentive Options: On January 15, 2026, DiaMedica granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on the grant date, ensuring that employees have a strong financial incentive to remain with the company long-term.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments thereafter, designed to encourage continued service and enhance employee loyalty.
- Strategic Focus: DiaMedica is dedicated to developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, and this stock option grant not only attracts talent but also supports its long-term growth in the biopharmaceutical sector.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Options Grant: On January 15, 2026, DiaMedica Therapeutics granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on January 15, 2026, indicating the company's commitment to employee incentives.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments, ensuring long-term incentives for employees who continue their service with the company.
- Strategic Implications: This options grant not only enhances the company's ability to attract and retain talent but also reflects DiaMedica's ongoing commitment to growth in the clinical-stage biopharmaceutical sector and investment in its workforce.
See More
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
See More
DiaMedica Engages FDA for DM199 Preclinical Study Clarity
- FDA Meeting Outcomes: DiaMedica's in-person meeting with the FDA confirmed the need for an additional non-clinical study to evaluate DM199 for preeclampsia, with results expected by Q2 2026, thereby providing crucial regulatory clarity for the IND submission.
- Clinical Trial Progress: The ongoing Phase 2 trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia, with interim data showing significant reductions in blood pressure and no placental transfer, indicating promising safety and efficacy.
- R&D Strategy: As the first pharmaceutical-grade recombinant form of human tissue kallikrein-1, DM199 targets preeclampsia, fetal growth restriction, and acute ischemic stroke, showcasing potential competitiveness in the global market, particularly in Asia.
- Future Outlook: DiaMedica plans to maintain ongoing engagement with the FDA to advance DM199's development, aiming to provide new treatment options for women facing preeclampsia, aligning with global demands for improved maternal and neonatal health.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
DiaMedica to Participate in Three Investment Conferences
- Investment Conference Schedule: DiaMedica Therapeutics will participate in the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, in Boston, where CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in a fireside chat, showcasing the company's latest advancements in treating serious ischemic diseases.
- Global Healthcare Conference: The company will also attend the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where CEO Rick Pauls will conduct a fireside chat, further enhancing the company's visibility among investors.
- Presentation Opportunity: On March 11, 2026, at the Leerink Partners Global Healthcare Conference, Rick Pauls will present the company, aiming to attract potential investors and highlight DiaMedica's R&D achievements and future plans.
- Management Interaction: DiaMedica encourages arrangements for 1-on-1 meetings with management to facilitate deeper engagement with investors, further strengthening the relationship between the company and its investors.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Incentive Options: On January 15, 2026, DiaMedica granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on the grant date, ensuring that employees have a strong financial incentive to remain with the company long-term.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments thereafter, designed to encourage continued service and enhance employee loyalty.
- Strategic Focus: DiaMedica is dedicated to developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, and this stock option grant not only attracts talent but also supports its long-term growth in the biopharmaceutical sector.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Options Grant: On January 15, 2026, DiaMedica Therapeutics granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on January 15, 2026, indicating the company's commitment to employee incentives.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments, ensuring long-term incentives for employees who continue their service with the company.
- Strategic Implications: This options grant not only enhances the company's ability to attract and retain talent but also reflects DiaMedica's ongoing commitment to growth in the clinical-stage biopharmaceutical sector and investment in its workforce.
See More
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
See More
DiaMedica Engages FDA for DM199 Preclinical Study Clarity
- FDA Meeting Outcomes: DiaMedica's in-person meeting with the FDA confirmed the need for an additional non-clinical study to evaluate DM199 for preeclampsia, with results expected by Q2 2026, thereby providing crucial regulatory clarity for the IND submission.
- Clinical Trial Progress: The ongoing Phase 2 trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia, with interim data showing significant reductions in blood pressure and no placental transfer, indicating promising safety and efficacy.
- R&D Strategy: As the first pharmaceutical-grade recombinant form of human tissue kallikrein-1, DM199 targets preeclampsia, fetal growth restriction, and acute ischemic stroke, showcasing potential competitiveness in the global market, particularly in Asia.
- Future Outlook: DiaMedica plans to maintain ongoing engagement with the FDA to advance DM199's development, aiming to provide new treatment options for women facing preeclampsia, aligning with global demands for improved maternal and neonatal health.
See More
